

# Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT06817889

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Fred Hutchinson Cancer Center
Enrollment	60 participants

## Key Eligibility Criteria

---

### Inclusion (21)

- Aged e 18 years
- Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)
- RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \[PCR\] or respiratory viral panel \[RVP\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing)
- Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies)
- Have a hematologic malignancy and/or autoimmune disease and received one of the following treatments relative to RSV diagnosis date:  
... and 16 more (see full listing online)

### Exclusion (18)

- Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for e 24 hours within the prior 7 days, and/or expected to receive anti-RSV direct-acting antiviral therapies for RSV during the course of the study at the time of screening
- Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode
- Received any investigational anti-RSV monoclonal antibodies or off-label use of approved anti-RSV monoclonal antibodies within \< 4 months or \< 5 half-lives, whichever is longer, before screening, or expected to receive anti-RSV monoclonal antibodies during the course of the study at the time of screening
- Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen
- Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines  
... and 13 more (see full listing online)

## Locations (3 total)

---

City of Hope Comprehensive Cancer Center, Duarte, California, United States  
MD Anderson Cancer Center, Houston, Texas, United States  
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

---

<https://clinicaltrials.gov/study/NCT06817889>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).